prs_id	slug	legacy_id	legacy_model	prswebprefix	trait_code	trait_name	trait_type	description	cohort	cohort_label	method	gwas_source	reference_label	reference_url	snp_count	p_value	pseudo_r2	brier_score	mse	aauc	aauc_ci	effect_metric	top_effect_1	top_effect_1_ci	top_or_1	top_or_1_ci	top_effect_2	top_effect_2_ci	top_or_2	top_or_2_ci	top_effect_5	top_effect_5_ci	top_or_5	top_or_5_ci	top_effect_10	top_effect_10_ci	top_or_10	top_or_10_ci	top_effect_25	top_effect_25_ci	top_or_25	top_or_25_ci	q1_vs_q2_effect	q1_vs_q2_effect_ci	q1_vs_q2_p_value	q1_vs_q3_effect	q1_vs_q3_effect_ci	q1_vs_q3_p_value	q1_vs_q4_effect	q1_vs_q4_effect_ci	q1_vs_q4_p_value	nominally_significant	reversed_effect_warning	underpowered_warning	upload_to_portal	sex	cases	controls	genome_build	tuning_parameter	weights_external_url	weights_url	phewas_download_url	exclusion_download_url	last_updated
prsweb-phecode185-20001-1044-p-5e-05-mgi-20200608	prsweb-phecode185-20001-1044-p-5e-05-mgi-20200608	PRSWEB_PHECODE185_20001-1044_P_5e-05_MGI_20200608	P_5e-05	PRSWEB_PHECODE185_20001-1044_P_5e-05_MGI_20200608	185	Cancer code, self-reported: prostate cancer	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-05)	UKB GWAS (PHESANT)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	203	1.3e-22	0.0295084	0.152		0.591	0.573-0.611	OR	1.82	1.07-3.11	1.82	1.07-3.11	1.39	0.907-2.12	1.39	0.907-2.12	1.95	1.52-2.51	1.95	1.52-2.51	1.85	1.53-2.24	1.85	1.53-2.24	1.73	1.5-1.99	1.73	1.5-1.99	1.72	1.38-2.14	1.25e-06	1.91	1.54-2.36	2.47e-09	2.62	2.14-3.21	1.57e-20	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode185-c3-prostate-p-5e-05-mgi-20200608	prsweb-phecode185-c3-prostate-p-5e-05-mgi-20200608	PRSWEB_PHECODE185_C3-PROSTATE_P_5e-05_MGI_20200608	P_5e-05	PRSWEB_PHECODE185_C3-PROSTATE_P_5e-05_MGI_20200608	185	Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-05)	UKB GWAS (FINNGEN)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	290	7.7e-38	0.0604999	0.149		0.626	0.607-0.644	OR	2.41	1.45-4.01	2.41	1.45-4.01	2.53	1.77-3.62	2.53	1.77-3.62	2.26	1.77-2.89	2.26	1.77-2.89	2.14	1.78-2.58	2.14	1.78-2.58	2.21	1.92-2.54	2.21	1.92-2.54	1.12	0.886-1.41	0.351	1.95	1.58-2.41	5.79e-10	2.99	2.44-3.66	1.85e-26	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode185-c61-p-5e-05-mgi-20200608	prsweb-phecode185-c61-p-5e-05-mgi-20200608	PRSWEB_PHECODE185_C61_P_5e-05_MGI_20200608	P_5e-05	PRSWEB_PHECODE185_C61_P_5e-05_MGI_20200608	185	Diagnoses - main ICD10: C61 Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-05)	UKB GWAS (ICD10)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	256	6.9e-31	0.0475713	0.15		0.61	0.591-0.629	OR	2.22	1.36-3.63	2.22	1.36-3.63	2.96	2.1-4.17	2.96	2.1-4.17	2.33	1.83-2.97	2.33	1.83-2.97	2.18	1.81-2.62	2.18	1.81-2.62	1.93	1.67-2.22	1.93	1.67-2.22	1.47	1.18-1.83	0.000644	1.87	1.51-2.32	7.19e-09	2.77	2.26-3.39	7.65e-23	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-05-mgi-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-05-mgi-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-05_MGI_20200608	P_5e-05	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-05_MGI_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	MGI	Michigan Genomics Initiative	Fixed threshold (5e-05)	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	124	3.6e-53	0.0666721	0.147		0.646	0.627-0.664	OR	3.41	2.17-5.35	3.41	2.17-5.35	3.39	2.43-4.73	3.39	2.43-4.73	2.74	2.17-3.45	2.74	2.17-3.45	2.73	2.29-3.27	2.73	2.29-3.27	2.5	2.17-2.87	2.5	2.17-2.87	1.62	1.27-2.05	8.09e-05	2.38	1.9-2.99	4.88e-14	4.08	3.3-5.06	5.87e-38	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode185-pca-practical-p-5e-05-mgi-20200608	prsweb-phecode185-pca-practical-p-5e-05-mgi-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-05_MGI_20200608	P_5e-05	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-05_MGI_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	MGI	Michigan Genomics Initiative	Fixed threshold (5e-05)	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	1223	9.1e-65	0.0891174	0.145		0.668	0.651-0.685	OR	3.62	2.27-5.76	3.62	2.27-5.76	3.24	2.3-4.55	3.24	2.3-4.55	2.99	2.38-3.75	2.99	2.38-3.75	2.78	2.33-3.32	2.78	2.33-3.32	3.06	2.66-3.52	3.06	2.66-3.52	1.8	1.41-2.31	3.1e-06	2.44	1.92-3.1	2.54e-13	5.25	4.2-6.57	5.1e-48	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode185-ukbb-saige-hrc-x185-p-5e-05-mgi-20200608	prsweb-phecode185-ukbb-saige-hrc-x185-p-5e-05-mgi-20200608	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-05_MGI_20200608	P_5e-05	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-05_MGI_20200608	185	Cancer of prostate	Binary	ICD9 and ICD10 based PheWAS codes	MGI	Michigan Genomics Initiative	Fixed threshold (5e-05)	UKB GWAS (PheCode)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	243	7.5e-35	0.0526162	0.15		0.616	0.598-0.634	OR	2.9	1.79-4.7	2.9	1.79-4.7	2.35	1.64-3.39	2.35	1.64-3.39	2.4	1.89-3.06	2.4	1.89-3.06	2.17	1.81-2.61	2.17	1.81-2.61	2.1	1.83-2.42	2.1	1.83-2.42	1.36	1.09-1.71	0.00746	1.83	1.48-2.27	2.23e-08	2.95	2.41-3.61	1.23e-25	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-05					2020-06-08
prsweb-phecode185-20001-1044-p-5e-06-mgi-20200608	prsweb-phecode185-20001-1044-p-5e-06-mgi-20200608	PRSWEB_PHECODE185_20001-1044_P_5e-06_MGI_20200608	P_5e-06	PRSWEB_PHECODE185_20001-1044_P_5e-06_MGI_20200608	185	Cancer code, self-reported: prostate cancer	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-06)	UKB GWAS (PHESANT)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	56	2e-31	0.0397989	0.15		0.609	0.591-0.628	OR	3.37	2.14-5.3	3.37	2.14-5.3	3.05	2.18-4.28	3.05	2.18-4.28	2.31	1.82-2.94	2.31	1.82-2.94	2.17	1.81-2.61	2.17	1.81-2.61	1.85	1.6-2.13	1.85	1.6-2.13	1.6	1.28-2	3.07e-05	2.12	1.71-2.63	6.92e-12	2.9	2.36-3.57	1.03e-23	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode185-c3-prostate-p-5e-06-mgi-20200608	prsweb-phecode185-c3-prostate-p-5e-06-mgi-20200608	PRSWEB_PHECODE185_C3-PROSTATE_P_5e-06_MGI_20200608	P_5e-06	PRSWEB_PHECODE185_C3-PROSTATE_P_5e-06_MGI_20200608	185	Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-06)	UKB GWAS (FINNGEN)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	118	1.6e-44	0.0639707	0.148		0.633	0.615-0.651	OR	3.22	2.03-5.09	3.22	2.03-5.09	3.06	2.19-4.29	3.06	2.19-4.29	2.97	2.37-3.73	2.97	2.37-3.73	2.54	2.12-3.04	2.54	2.12-3.04	2.19	1.9-2.52	2.19	1.9-2.52	1.61	1.28-2.03	5.61e-05	2.23	1.79-2.79	1.22e-12	3.52	2.85-4.34	1.83e-31	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode185-c61-p-5e-06-mgi-20200608	prsweb-phecode185-c61-p-5e-06-mgi-20200608	PRSWEB_PHECODE185_C61_P_5e-06_MGI_20200608	P_5e-06	PRSWEB_PHECODE185_C61_P_5e-06_MGI_20200608	185	Diagnoses - main ICD10: C61 Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-06)	UKB GWAS (ICD10)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	80	2.6e-38	0.0566154	0.149		0.621	0.603-0.64	OR	2.65	1.63-4.3	2.65	1.63-4.3	2.88	2.04-4.08	2.88	2.04-4.08	2.59	2.05-3.27	2.59	2.05-3.27	2.41	2.01-2.89	2.41	2.01-2.89	2.02	1.75-2.32	2.02	1.75-2.32	1.44	1.15-1.8	0.00161	2.06	1.66-2.54	3.95e-11	3.02	2.46-3.72	9.37e-26	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-06-mgi-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-06-mgi-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-06_MGI_20200608	P_5e-06	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-06_MGI_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	MGI	Michigan Genomics Initiative	Fixed threshold (5e-06)	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	124	3.6e-53	0.0666721	0.147		0.646	0.627-0.664	OR	3.41	2.17-5.35	3.41	2.17-5.35	3.39	2.43-4.73	3.39	2.43-4.73	2.74	2.17-3.45	2.74	2.17-3.45	2.73	2.29-3.27	2.73	2.29-3.27	2.5	2.17-2.87	2.5	2.17-2.87	1.62	1.27-2.05	8.09e-05	2.38	1.9-2.99	4.88e-14	4.08	3.3-5.06	5.87e-38	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode185-pca-practical-p-5e-06-mgi-20200608	prsweb-phecode185-pca-practical-p-5e-06-mgi-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-06_MGI_20200608	P_5e-06	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-06_MGI_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	MGI	Michigan Genomics Initiative	Fixed threshold (5e-06)	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	691	3.1e-63	0.0849946	0.145		0.666	0.649-0.683	OR	4.51	2.94-6.94	4.51	2.94-6.94	4.3	3.12-5.92	4.3	3.12-5.92	2.81	2.24-3.54	2.81	2.24-3.54	2.79	2.34-3.33	2.79	2.34-3.33	2.9	2.52-3.34	2.9	2.52-3.34	1.6	1.25-2.05	0.000188	2.56	2.03-3.24	3.46e-15	4.9	3.93-6.1	1.35e-45	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode185-ukbb-saige-hrc-x185-p-5e-06-mgi-20200608	prsweb-phecode185-ukbb-saige-hrc-x185-p-5e-06-mgi-20200608	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-06_MGI_20200608	P_5e-06	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-06_MGI_20200608	185	Cancer of prostate	Binary	ICD9 and ICD10 based PheWAS codes	MGI	Michigan Genomics Initiative	Fixed threshold (5e-06)	UKB GWAS (PheCode)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	110	3e-41	0.0592476	0.149		0.628	0.61-0.647	OR	3.55	2.26-5.58	3.55	2.26-5.58	2.79	1.97-3.94	2.79	1.97-3.94	2.78	2.2-3.51	2.78	2.2-3.51	2.51	2.1-3	2.51	2.1-3	2.16	1.88-2.49	2.16	1.88-2.49	1.39	1.1-1.76	0.00578	2.16	1.75-2.68	1.7e-12	3.24	2.63-3.98	5.8e-29	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-06					2020-06-08
prsweb-phecode185-20001-1044-p-5e-07-mgi-20200608	prsweb-phecode185-20001-1044-p-5e-07-mgi-20200608	PRSWEB_PHECODE185_20001-1044_P_5e-07_MGI_20200608	P_5e-07	PRSWEB_PHECODE185_20001-1044_P_5e-07_MGI_20200608	185	Cancer code, self-reported: prostate cancer	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-07)	UKB GWAS (PHESANT)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	32	7.3e-29	0.0374154	0.151		0.607	0.59-0.626	OR	2.83	1.76-4.53	2.83	1.76-4.53	2.48	1.73-3.55	2.48	1.73-3.55	1.98	1.54-2.54	1.98	1.54-2.54	1.87	1.55-2.26	1.87	1.55-2.26	1.73	1.5-2	1.73	1.5-2	1.43	1.14-1.79	0.00175	2.25	1.82-2.77	3.01e-14	2.71	2.2-3.33	2.84e-21	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode185-c3-prostate-p-5e-07-mgi-20200608	prsweb-phecode185-c3-prostate-p-5e-07-mgi-20200608	PRSWEB_PHECODE185_C3-PROSTATE_P_5e-07_MGI_20200608	P_5e-07	PRSWEB_PHECODE185_C3-PROSTATE_P_5e-07_MGI_20200608	185	Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-07)	UKB GWAS (FINNGEN)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	67	1.8e-47	0.0614117	0.148		0.638	0.62-0.656	OR	3.69	2.36-5.75	3.69	2.36-5.75	2.71	1.92-3.83	2.71	1.92-3.83	2.98	2.37-3.75	2.98	2.37-3.75	2.6	2.17-3.11	2.6	2.17-3.11	2.43	2.11-2.8	2.43	2.11-2.8	1.5	1.19-1.89	0.000563	1.99	1.6-2.48	8.2e-10	3.61	2.93-4.45	1.62e-33	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode185-c61-p-5e-07-mgi-20200608	prsweb-phecode185-c61-p-5e-07-mgi-20200608	PRSWEB_PHECODE185_C61_P_5e-07_MGI_20200608	P_5e-07	PRSWEB_PHECODE185_C61_P_5e-07_MGI_20200608	185	Diagnoses - main ICD10: C61 Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-07)	UKB GWAS (ICD10)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	47	5e-37	0.0626774	0.149		0.619	0.601-0.637	OR	3.1	1.96-4.92	3.1	1.96-4.92	2.88	2.04-4.06	2.88	2.04-4.06	2.59	2.05-3.27	2.59	2.05-3.27	2.18	1.82-2.62	2.18	1.82-2.62	1.95	1.69-2.24	1.95	1.69-2.24	1.56	1.24-1.95	0.000138	2.24	1.81-2.77	1.63e-13	3.11	2.53-3.83	8.39e-27	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-07-mgi-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-07-mgi-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-07_MGI_20200608	P_5e-07	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-07_MGI_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	MGI	Michigan Genomics Initiative	Fixed threshold (5e-07)	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	123	7e-53	0.066706	0.147		0.646	0.627-0.663	OR	3.64	2.33-5.68	3.64	2.33-5.68	3.44	2.47-4.81	3.44	2.47-4.81	2.68	2.12-3.38	2.68	2.12-3.38	2.69	2.25-3.22	2.69	2.25-3.22	2.52	2.19-2.9	2.52	2.19-2.9	1.68	1.33-2.14	1.82e-05	2.38	1.89-2.99	9.14e-14	4.17	3.36-5.17	9.7e-39	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode185-pca-practical-p-5e-07-mgi-20200608	prsweb-phecode185-pca-practical-p-5e-07-mgi-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-07_MGI_20200608	P_5e-07	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-07_MGI_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	MGI	Michigan Genomics Initiative	Fixed threshold (5e-07)	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	492	2e-56	0.0877555	0.146		0.653	0.636-0.673	OR	4.62	2.99-7.13	4.62	2.99-7.13	3.47	2.49-4.82	3.47	2.49-4.82	2.76	2.19-3.48	2.76	2.19-3.48	2.68	2.24-3.2	2.68	2.24-3.2	2.67	2.32-3.07	2.67	2.32-3.07	1.79	1.41-2.28	1.82e-06	2.34	1.85-2.95	1.2e-12	4.5	3.61-5.59	1.82e-41	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode185-ukbb-saige-hrc-x185-p-5e-07-mgi-20200608	prsweb-phecode185-ukbb-saige-hrc-x185-p-5e-07-mgi-20200608	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-07_MGI_20200608	P_5e-07	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-07_MGI_20200608	185	Cancer of prostate	Binary	ICD9 and ICD10 based PheWAS codes	MGI	Michigan Genomics Initiative	Fixed threshold (5e-07)	UKB GWAS (PheCode)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	64	2.6e-43	0.0576157	0.148		0.631	0.612-0.649	OR	3.8	2.44-5.92	3.8	2.44-5.92	3.87	2.8-5.35	3.87	2.8-5.35	2.94	2.33-3.7	2.94	2.33-3.7	2.36	1.97-2.83	2.36	1.97-2.83	2.15	1.87-2.47	2.15	1.87-2.47	1.22	0.972-1.54	0.0867	2.08	1.68-2.57	1.22e-11	3.09	2.52-3.79	2.46e-27	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-07					2020-06-08
prsweb-phecode185-20001-1044-p-5e-09-mgi-20200608	prsweb-phecode185-20001-1044-p-5e-09-mgi-20200608	PRSWEB_PHECODE185_20001-1044_P_5e-09_MGI_20200608	P_5e-09	PRSWEB_PHECODE185_20001-1044_P_5e-09_MGI_20200608	185	Cancer code, self-reported: prostate cancer	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-09)	UKB GWAS (PHESANT)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	14	3.7e-24	0.0350443	0.151		0.591	0.573-0.61	OR	1.67	0.971-2.87	1.67	0.971-2.87	2.47	1.72-3.55	2.47	1.72-3.55	2.08	1.62-2.68	2.08	1.62-2.68	1.75	1.44-2.13	1.75	1.44-2.13	1.8	1.56-2.07	1.8	1.56-2.07	1.38	1.11-1.71	0.00347	1.74	1.41-2.14	2.01e-07	2.49	2.03-3.05	1.08e-18	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode185-c3-prostate-p-5e-09-mgi-20200608	prsweb-phecode185-c3-prostate-p-5e-09-mgi-20200608	PRSWEB_PHECODE185_C3-PROSTATE_P_5e-09_MGI_20200608	P_5e-09	PRSWEB_PHECODE185_C3-PROSTATE_P_5e-09_MGI_20200608	185	Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-09)	UKB GWAS (FINNGEN)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	43	2.1e-39	0.0561884	0.149		0.624	0.605-0.642	OR	3.06	1.93-4.85	3.06	1.93-4.85	2.96	2.1-4.19	2.96	2.1-4.19	2.53	1.99-3.2	2.53	1.99-3.2	2.42	2.02-2.89	2.42	2.02-2.89	2.03	1.76-2.34	2.03	1.76-2.34	1.48	1.18-1.85	0.00066	2.06	1.66-2.55	3.25e-11	3.08	2.5-3.78	1.02e-26	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode185-c61-p-5e-09-mgi-20200608	prsweb-phecode185-c61-p-5e-09-mgi-20200608	PRSWEB_PHECODE185_C61_P_5e-09_MGI_20200608	P_5e-09	PRSWEB_PHECODE185_C61_P_5e-09_MGI_20200608	185	Diagnoses - main ICD10: C61 Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	Fixed threshold (5e-09)	UKB GWAS (ICD10)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	21	2.1e-33	0.0466292	0.15		0.61	0.591-0.628	OR	2.64	1.63-4.27	2.64	1.63-4.27	2.55	1.78-3.64	2.55	1.78-3.64	2.54	2-3.22	2.54	2-3.22	2.22	1.85-2.67	2.22	1.85-2.67	1.93	1.67-2.22	1.93	1.67-2.22	1.55	1.25-1.92	7.69e-05	1.78	1.44-2.2	9.36e-08	2.84	2.31-3.47	8.89e-24	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-09-mgi-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-09-mgi-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-09_MGI_20200608	P_5e-09	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-09_MGI_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	MGI	Michigan Genomics Initiative	Fixed threshold (5e-09)	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	86	4.3e-51	0.0563016	0.147		0.643	0.625-0.661	OR	2.97	1.85-4.75	2.97	1.85-4.75	3.11	2.22-4.35	3.11	2.22-4.35	2.62	2.08-3.3	2.62	2.08-3.3	2.55	2.13-3.05	2.55	2.13-3.05	2.43	2.11-2.8	2.43	2.11-2.8	1.6	1.26-2.03	0.000131	2.4	1.92-3.01	1.79e-14	4.07	3.27-5.05	9.39e-37	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode185-pca-practical-p-5e-09-mgi-20200608	prsweb-phecode185-pca-practical-p-5e-09-mgi-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-09_MGI_20200608	P_5e-09	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-09_MGI_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	MGI	Michigan Genomics Initiative	Fixed threshold (5e-09)	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	293	1.4e-54	0.0817148	0.146		0.648	0.63-0.665	OR	3.99	2.57-6.21	3.99	2.57-6.21	3.24	2.31-4.54	3.24	2.31-4.54	3.06	2.44-3.84	3.06	2.44-3.84	2.73	2.29-3.26	2.73	2.29-3.26	2.63	2.28-3.03	2.63	2.28-3.03	1.92	1.51-2.44	8.25e-08	2.27	1.79-2.87	8.14e-12	4.52	3.62-5.64	8.75e-41	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode185-ukbb-saige-hrc-x185-p-5e-09-mgi-20200608	prsweb-phecode185-ukbb-saige-hrc-x185-p-5e-09-mgi-20200608	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-09_MGI_20200608	P_5e-09	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-09_MGI_20200608	185	Cancer of prostate	Binary	ICD9 and ICD10 based PheWAS codes	MGI	Michigan Genomics Initiative	Fixed threshold (5e-09)	UKB GWAS (PheCode)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	32	1e-40	0.0519668	0.149		0.627	0.609-0.644	OR	2.51	1.54-4.07	2.51	1.54-4.07	2.93	2.08-4.12	2.93	2.08-4.12	2.52	1.99-3.2	2.52	1.99-3.2	2.31	1.93-2.78	2.31	1.93-2.78	2.12	1.84-2.44	2.12	1.84-2.44	1.37	1.09-1.73	0.00683	2.19	1.77-2.71	6e-13	3.23	2.62-3.97	1.24e-28	True	False	False	False	Male	1190	4417	GRCh37/hg19	P<=5e-09					2020-06-08
prsweb-phecode185-20001-1044-p-5e-08-mgi-20200608	prsweb-phecode185-20001-1044-p-5e-08-mgi-20200608	PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608	P_5e-08	PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608	185	Cancer code, self-reported: prostate cancer	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	GWAS Hits	UKB GWAS (PHESANT)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	21	3.3e-23	0.0330165	0.151		0.596	0.579-0.615	OR	2.39	1.41-4.03	2.39	1.41-4.03	2.83	1.99-4.04	2.83	1.99-4.04	2.06	1.61-2.65	2.06	1.61-2.65	1.85	1.53-2.25	1.85	1.53-2.25	1.73	1.5-2	1.73	1.5-2	1.46	1.18-1.81	0.000516	1.78	1.44-2.18	5.49e-08	2.45	2-3	2.54e-18	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000565/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000565/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_20001-1044_P_5e-08_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-c3-prostate-p-5e-08-mgi-20200608	prsweb-phecode185-c3-prostate-p-5e-08-mgi-20200608	PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608	P_5e-08	PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608	185	Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	GWAS Hits	UKB GWAS (FINNGEN)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	49	3.5e-43	0.0562038	0.148		0.63	0.613-0.648	OR	2.86	1.79-4.57	2.86	1.79-4.57	3.35	2.39-4.69	3.35	2.39-4.69	2.8	2.22-3.53	2.8	2.22-3.53	2.49	2.08-2.98	2.49	2.08-2.98	2.17	1.88-2.5	2.17	1.88-2.5	1.42	1.13-1.79	0.00241	1.99	1.61-2.47	3.06e-10	3.18	2.59-3.9	2.14e-28	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000569/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000569/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C3-PROSTATE_P_5e-08_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-c61-p-5e-08-mgi-20200608	prsweb-phecode185-c61-p-5e-08-mgi-20200608	PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608	P_5e-08	PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608	185	Diagnoses - main ICD10: C61 Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	GWAS Hits	UKB GWAS (ICD10)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	31	2.6e-40	0.054533	0.149		0.622	0.603-0.641	OR	2.93	1.83-4.7	2.93	1.83-4.7	3.01	2.14-4.22	3.01	2.14-4.22	2.97	2.36-3.72	2.97	2.36-3.72	2.39	2-2.87	2.39	2-2.87	2.07	1.8-2.39	2.07	1.8-2.39	1.34	1.07-1.67	0.0106	1.86	1.51-2.3	7.99e-09	2.94	2.4-3.6	1.71e-25	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000573/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000573/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C61_P_5e-08_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-08-mgi-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-p-5e-08-mgi-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608	P_5e-08	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	MGI	Michigan Genomics Initiative	GWAS Hits	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	117	1.9e-53	0.062802	0.147		0.646	0.627-0.665	OR	3.57	2.29-5.57	3.57	2.29-5.57	2.91	2.06-4.1	2.91	2.06-4.1	2.97	2.36-3.73	2.97	2.36-3.73	2.75	2.3-3.29	2.75	2.3-3.29	2.66	2.31-3.06	2.66	2.31-3.06	1.39	1.1-1.76	0.00637	2.1	1.68-2.62	5.67e-11	3.92	3.18-4.83	1.01e-37	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000577/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000577/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_P_5e-08_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-pca-practical-p-5e-08-mgi-20200608	prsweb-phecode185-pca-practical-p-5e-08-mgi-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608	P_5e-08	PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	MGI	Michigan Genomics Initiative	GWAS Hits	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	377	1.8e-55	0.0888129	0.146		0.651	0.634-0.669	OR	4.44	2.87-6.87	4.44	2.87-6.87	3.3	2.36-4.61	3.3	2.36-4.61	3.02	2.4-3.8	3.02	2.4-3.8	2.72	2.27-3.25	2.72	2.27-3.25	2.65	2.3-3.05	2.65	2.3-3.05	1.8	1.42-2.29	1.34e-06	2.28	1.81-2.88	4.69e-12	4.45	3.57-5.54	1.53e-40	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000581/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000581/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_P_5e-08_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-ukbb-saige-hrc-x185-p-5e-08-mgi-20200608	prsweb-phecode185-ukbb-saige-hrc-x185-p-5e-08-mgi-20200608	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608	P_5e-08	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608	185	Cancer of prostate	Binary	ICD9 and ICD10 based PheWAS codes	MGI	Michigan Genomics Initiative	GWAS Hits	UKB GWAS (PheCode)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	42	5.8e-43	0.05481	0.148		0.63	0.612-0.648	OR	3.14	1.99-4.96	3.14	1.99-4.96	3.06	2.17-4.31	3.06	2.17-4.31	2.68	2.12-3.38	2.68	2.12-3.38	2.34	1.95-2.8	2.34	1.95-2.8	2.11	1.83-2.43	2.11	1.83-2.43	1.32	1.05-1.66	0.0192	2.31	1.86-2.87	2.72e-14	3.26	2.65-4.01	9.64e-29	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=5e-08	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000589/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000589/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_P_5e-08_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-20001-1044-pt-mgi-20200608	prsweb-phecode185-20001-1044-pt-mgi-20200608	PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608	P&T	PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608	185	Cancer code, self-reported: prostate cancer	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	P&T	UKB GWAS (PHESANT)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	78	9e-31	0.0409883	0.15		0.608	0.59-0.628	OR	3.17	1.98-5.06	3.17	1.98-5.06	3.34	2.39-4.65	3.34	2.39-4.65	2.65	2.1-3.35	2.65	2.1-3.35	2.12	1.76-2.55	2.12	1.76-2.55	1.86	1.61-2.14	1.86	1.61-2.14	1.58	1.26-1.97	6.09e-05	2.09	1.69-2.59	9.84e-12	2.84	2.32-3.49	1.46e-23	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=1e-05	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000567/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000567/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_20001-1044_PT_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-c3-prostate-pt-mgi-20200608	prsweb-phecode185-c3-prostate-pt-mgi-20200608	PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608	P&T	PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608	185	Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	P&T	UKB GWAS (FINNGEN)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	100	2.3e-45	0.0656138	0.148		0.634	0.617-0.653	OR	2.96	1.85-4.74	2.96	1.85-4.74	3	2.13-4.22	3	2.13-4.22	2.73	2.16-3.44	2.73	2.16-3.44	2.46	2.05-2.94	2.46	2.05-2.94	2.32	2.02-2.68	2.32	2.02-2.68	1.62	1.28-2.04	4.6e-05	2.17	1.74-2.71	9.85e-12	3.7	2.99-4.57	9.18e-34	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=2.51e-06	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000571/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000571/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C3-PROSTATE_PT_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-c61-pt-mgi-20200608	prsweb-phecode185-c61-pt-mgi-20200608	PRSWEB_PHECODE185_C61_PT_MGI_20200608	P&T	PRSWEB_PHECODE185_C61_PT_MGI_20200608	185	Diagnoses - main ICD10: C61 Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	P&T	UKB GWAS (ICD10)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	47	5e-37	0.0626774	0.149		0.619	0.601-0.637	OR	3.1	1.96-4.92	3.1	1.96-4.92	2.88	2.04-4.06	2.88	2.04-4.06	2.59	2.05-3.27	2.59	2.05-3.27	2.18	1.82-2.62	2.18	1.82-2.62	1.95	1.69-2.24	1.95	1.69-2.24	1.56	1.24-1.95	0.000138	2.24	1.81-2.77	1.63e-13	3.11	2.53-3.83	8.39e-27	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=5e-07	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000575/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000575/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C61_PT_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C61_PT_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-gwas-catalog-r2019-05-03-x185-pt-mgi-20200608	prsweb-phecode185-gwas-catalog-r2019-05-03-x185-pt-mgi-20200608	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608	P&T	PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608	185	Prostate cancer;Prostate cancer (early onset)	Binary	157 unique SNPs	MGI	Michigan Genomics Initiative	P&T	GWAS Catalog (2019-05-03)	17401363;17401366;17603485;18264096;18264097;18264098;19117981;19767754;21743057;21743467;23104005;23535732;24740154;25939597;27262462;29892016;30410027	https://www.ncbi.nlm.nih.gov/pubmed/?term=17401363+17401366+17603485+18264096+18264097+18264098+19117981+19767754+21743057+21743467+23104005+23535732+24740154+25939597+27262462+29892016+30410027	122	7.2e-53	0.0667357	0.147		0.646	0.627-0.664	OR	3.53	2.26-5.51	3.53	2.26-5.51	3.59	2.58-4.99	3.59	2.58-4.99	2.74	2.17-3.46	2.74	2.17-3.46	2.71	2.27-3.24	2.71	2.27-3.24	2.45	2.13-2.82	2.45	2.13-2.82	1.59	1.25-2.02	0.000136	2.43	1.94-3.05	1.28e-14	4.02	3.25-4.98	3e-37	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=2.51e-07	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000579/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000579/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_GWAS-Catalog-r2019-05-03-X185_PT_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-pca-practical-pt-mgi-20200608	prsweb-phecode185-pca-practical-pt-mgi-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608	P&T	PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	MGI	Michigan Genomics Initiative	P&T	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	1301	1.6e-65	0.0897595	0.145		0.67	0.652-0.688	OR	3.3	2.06-5.29	3.3	2.06-5.29	2.96	2.08-4.2	2.96	2.08-4.2	3.01	2.39-3.78	3.01	2.39-3.78	2.85	2.39-3.4	2.85	2.39-3.4	3.07	2.67-3.53	3.07	2.67-3.53	1.92	1.49-2.46	3.79e-07	2.61	2.05-3.33	1.22e-14	5.6	4.45-7.04	3.14e-49	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=6.31e-05	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000585/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000585/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_PT_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-ukbb-saige-hrc-x185-pt-mgi-20200608	prsweb-phecode185-ukbb-saige-hrc-x185-pt-mgi-20200608	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608	P&T	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608	185	Cancer of prostate	Binary	ICD9 and ICD10 based PheWAS codes	MGI	Michigan Genomics Initiative	P&T	UKB GWAS (PheCode)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	80	5.9e-40	0.0595594	0.149		0.627	0.608-0.645	OR	3.18	2.01-5.02	3.18	2.01-5.02	3.57	2.57-4.95	3.57	2.57-4.95	2.85	2.26-3.58	2.85	2.26-3.58	2.21	1.84-2.66	2.21	1.84-2.66	2.13	1.85-2.45	2.13	1.85-2.45	1.46	1.17-1.84	0.00106	2.09	1.69-2.6	2.26e-11	3.21	2.61-3.94	1.4e-28	True	False	False	True	Male	1190	4417	GRCh37/hg19	P<=1.26e-06	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000591/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000591/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PT_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-20001-1044-prs-cs-mgi-20200608	prsweb-phecode185-20001-1044-prs-cs-mgi-20200608	PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608	PRS-CS	PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608	185	Cancer code, self-reported: prostate cancer	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	PRS-CS	UKB GWAS (PHESANT)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	1111494	4.8e-21	0.0209629	0.152		0.591	0.573-0.609	OR	2.85	1.76-4.62	2.85	1.76-4.62	2.43	1.68-3.5	2.43	1.68-3.5	1.88	1.45-2.43	1.88	1.45-2.43	1.59	1.31-1.95	1.59	1.31-1.95	1.74	1.51-2.01	1.74	1.51-2.01	1.11	0.898-1.37	0.335	1.66	1.36-2.04	8.27e-07	2.17	1.79-2.64	5.76e-15	True	False	False	True	Male	1190	4417	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000566/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000566/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_20001-1044_PRS-CS_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-c3-prostate-prs-cs-mgi-20200608	prsweb-phecode185-c3-prostate-prs-cs-mgi-20200608	PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608	PRS-CS	PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608	185	Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	PRS-CS	UKB GWAS (FINNGEN)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	1111493	2e-36	0.0413552	0.149		0.622	0.604-0.639	OR	2.66	1.63-4.34	2.66	1.63-4.34	2.61	1.82-3.74	2.61	1.82-3.74	2.21	1.72-2.83	2.21	1.72-2.83	2.15	1.79-2.6	2.15	1.79-2.6	2.06	1.79-2.37	2.06	1.79-2.37	1.36	1.09-1.71	0.00687	1.99	1.6-2.46	2.94e-10	2.96	2.42-3.64	1.7e-25	True	False	False	True	Male	1190	4417	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000570/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000570/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C3-PROSTATE_PRS-CS_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-c61-prs-cs-mgi-20200608	prsweb-phecode185-c61-prs-cs-mgi-20200608	PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608	PRS-CS	PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608	185	Diagnoses - main ICD10: C61 Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	PRS-CS	UKB GWAS (ICD10)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	1111493	2.3e-31	0.0256089	0.15		0.612	0.593-0.63	OR	2.09	1.24-3.52	2.09	1.24-3.52	2.55	1.79-3.63	2.55	1.79-3.63	2.54	2-3.21	2.54	2-3.21	2.21	1.84-2.66	2.21	1.84-2.66	1.95	1.69-2.25	1.95	1.69-2.25	1.42	1.14-1.77	0.00186	1.87	1.52-2.31	5.48e-09	2.78	2.27-3.4	3.33e-23	True	False	False	True	Male	1190	4417	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000574/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000574/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C61_PRS-CS_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-pca-practical-prs-cs-mgi-20200608	prsweb-phecode185-pca-practical-prs-cs-mgi-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608	PRS-CS	PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	MGI	Michigan Genomics Initiative	PRS-CS	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	1119311	6.9e-67	0.0898146	0.145		0.668	0.651-0.687	OR	3.61	2.28-5.72	3.61	2.28-5.72	3.95	2.86-5.45	3.95	2.86-5.45	3.79	3.04-4.73	3.79	3.04-4.73	3.16	2.65-3.76	3.16	2.65-3.76	2.66	2.31-3.06	2.66	2.31-3.06	2.26	1.74-2.93	1.13e-09	3.53	2.75-4.54	5.68e-23	5.96	4.68-7.58	1.15e-47	True	False	False	True	Male	1190	4417	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000583/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000583/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_PRS-CS_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-ukbb-saige-hrc-x185-prs-cs-mgi-20200608	prsweb-phecode185-ukbb-saige-hrc-x185-prs-cs-mgi-20200608	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608	PRS-CS	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608	185	Cancer of prostate	Binary	ICD9 and ICD10 based PheWAS codes	MGI	Michigan Genomics Initiative	PRS-CS	UKB GWAS (PheCode)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	1119236	3.8e-32	0.0350197	0.15		0.614	0.595-0.633	OR	2.32	1.42-3.78	2.32	1.42-3.78	2.46	1.72-3.53	2.46	1.72-3.53	2.56	2.02-3.26	2.56	2.02-3.26	2.11	1.75-2.55	2.11	1.75-2.55	1.85	1.61-2.13	1.85	1.61-2.13	1.65	1.32-2.06	1.02e-05	2.1	1.69-2.61	1.65e-11	2.89	2.35-3.56	9.25e-24	True	False	False	True	Male	1190	4417	GRCh37/hg19	auto	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000590/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000590/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_PRS-CS_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-20001-1044-lassosum-mgi-20200608	prsweb-phecode185-20001-1044-lassosum-mgi-20200608	PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608	Lassosum	PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608	185	Cancer code, self-reported: prostate cancer	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	lassosum	UKB GWAS (PHESANT)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	1401	3.5e-24	0.0398312	0.151		0.595	0.577-0.614	OR	1.53	0.88-2.66	1.53	0.88-2.66	2.03	1.39-2.97	2.03	1.39-2.97	1.99	1.54-2.55	1.99	1.54-2.55	1.98	1.64-2.39	1.98	1.64-2.39	1.67	1.45-1.93	1.67	1.45-1.93	1.29	1.04-1.61	0.0208	2	1.63-2.45	2.6e-11	2.41	1.97-2.95	1.32e-17	True	False	False	True	Male	1190	4417	GRCh37/hg19	s=0.9;Lambda=0.03793	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000568/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000568/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_20001-1044_LASSOSUM_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-c3-prostate-lassosum-mgi-20200608	prsweb-phecode185-c3-prostate-lassosum-mgi-20200608	PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608	Lassosum	PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608	185	Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	lassosum	UKB GWAS (FINNGEN)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	1809	3.2e-33	0.0527929	0.15		0.616	0.597-0.636	OR	4.03	2.59-6.28	4.03	2.59-6.28	2.87	2.03-4.05	2.87	2.03-4.05	2.26	1.77-2.87	2.26	1.77-2.87	1.93	1.6-2.33	1.93	1.6-2.33	1.91	1.65-2.2	1.91	1.65-2.2	1.33	1.06-1.66	0.0134	2.08	1.68-2.57	1.37e-11	2.78	2.26-3.4	8.33e-23	True	False	False	True	Male	1190	4417	GRCh37/hg19	s=0.5;Lambda=0.02336	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000572/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000572/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C3-PROSTATE_LASSOSUM_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-c61-lassosum-mgi-20200608	prsweb-phecode185-c61-lassosum-mgi-20200608	PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608	Lassosum	PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608	185	Diagnoses - main ICD10: C61 Malignant neoplasm of prostate	Binary	GWAS round 2: Results shared 1st August 2018. Imputed genotypes from HRC plus UK10K & 1000 Genomes reference panels as released by UK Biobank in March 2018.	MGI	Michigan Genomics Initiative	lassosum	UKB GWAS (ICD10)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	905	1.6e-29	0.0489243	0.151		0.607	0.589-0.627	OR	2.46	1.5-4.01	2.46	1.5-4.01	2.13	1.48-3.07	2.13	1.48-3.07	2.2	1.73-2.81	2.2	1.73-2.81	2	1.66-2.4	2	1.66-2.4	1.85	1.6-2.13	1.85	1.6-2.13	1.49	1.2-1.86	0.00037	2.07	1.67-2.56	2.4e-11	2.77	2.26-3.4	7.85e-23	True	False	False	True	Male	1190	4417	GRCh37/hg19	s=0.5;Lambda=0.02976	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000576/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000576/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_C61_LASSOSUM_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-pca-practical-lassosum-mgi-20200608	prsweb-phecode185-pca-practical-lassosum-mgi-20200608	PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608	Lassosum	PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608	185	Prostate cancer	Binary	"Meta analysis summary data
Meta summary association statistics for overall Prostate Cancer, as described in Schumacher, Al Olama, Berndt, et al. 2018 are provided.

Acknowledgements
When using these data, please cite: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Schumacher, Al Olama, Berndt, et al. Nature Genetics 2018, acknowledge “The PRACTICAL consortium, CRUK, BPC3, CAPS, PEGASUS”, and include the following:

The Prostate cancer genome-wide association analyses are supported by the Canadian Institutes of Health Research, European Commission’s Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C1287/A16563, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.
The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall’s. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

Genotyping of the OncoArray was funded by the US National Institutes of Health (NIH) [U19 CA 148537 for ELucidating Loci Involved in Prostate cancer SuscEptibility (ELLIPSE) project and X01HG007492 to the Center for Inherited Disease Research (CIDR) under contract number HHSN268201200008I] and by Cancer Research UK grant A8197/A16565. Additional analytic support was provided by NIH NCI U01 CA188392 (PI: Schumacher).

Funding for the iCOGS infrastructure came from: the European Community’s Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

The BPC3 was supported by the U.S. National Institutes of Health, National Cancer Institute (cooperative agreements U01-CA98233 to D.J.H., U01-CA98710 to S.M.G., U01-CA98216 toE.R., and U01-CA98758 to B.E.H., and Intramural Research Program of NIH/National Cancer Institute, Division of Cancer Epidemiology and Genetics).

CAPS GWAS study was supported by the Swedish Cancer Foundation (grant no 09-0677, 11-484, 12-823), the Cancer Risk Prediction Center (CRisP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3, 2014-2269)

PEGASUS was supported by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health.

Kindly send a copy of any publication that results from these data to PRACTICAL@icr.ac.uk

Terms of use
The nature of the data provided should not allow identification of individual subjects.
By downloading these data, you agree not to attempt to identify individual subjects, or repost these data to a third party website without permission."	MGI	Michigan Genomics Initiative	lassosum	Schumacher FR et al. 2019	29892016	https://www.ncbi.nlm.nih.gov/pubmed/?term=29892016	26418	3.3e-66	0.0919723	0.145		0.665	0.647-0.684	OR	4.92	3.21-7.55	4.92	3.21-7.55	3.98	2.88-5.5	3.98	2.88-5.5	3.26	2.6-4.08	3.26	2.6-4.08	2.98	2.5-3.56	2.98	2.5-3.56	2.78	2.41-3.2	2.78	2.41-3.2	1.94	1.51-2.49	2.37e-07	2.83	2.23-3.6	2.21e-17	5.35	4.25-6.73	1.21e-46	True	False	False	True	Male	1190	4417	GRCh37/hg19	s=0.5;Lambda=0.006952	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000587/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000587/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_Pca-PRACTICAL_LASSOSUM_MGI_20200608/exclusion.tsv	2020-06-08
prsweb-phecode185-ukbb-saige-hrc-x185-lassosum-mgi-20200608	prsweb-phecode185-ukbb-saige-hrc-x185-lassosum-mgi-20200608	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608	Lassosum	PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608	185	Cancer of prostate	Binary	ICD9 and ICD10 based PheWAS codes	MGI	Michigan Genomics Initiative	lassosum	UKB GWAS (PheCode)	UKB_GWAS	https://www.ncbi.nlm.nih.gov/pubmed/?term=30104761	1334	2.5e-33	0.0503	0.15		0.616	0.598-0.635	OR	2.55	1.55-4.2	2.55	1.55-4.2	2.33	1.6-3.38	2.33	1.6-3.38	2.28	1.79-2.9	2.28	1.79-2.9	2	1.66-2.42	2	1.66-2.42	1.88	1.63-2.17	1.88	1.63-2.17	1.53	1.22-1.92	0.00025	2.3	1.85-2.84	2.29e-14	3.01	2.44-3.71	2.89e-25	True	False	False	True	Male	1190	4417	GRCh37/hg19	s=0.5;Lambda=0.02336	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000592/ScoringFiles/	https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000592/ScoringFiles/	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608/all.tsv	/larsf/prsweb-data/cancerprsweb/releases/cancerprsweb_20200608/phewas/PRSWEB_PHECODE185_UKBB-SAIGE-HRC-X185_LASSOSUM_MGI_20200608/exclusion.tsv	2020-06-08